#India #financial results #Mumbai #Piramal Pharma #Q1 2027

Piramal Pharma Limited Reports Strong Performance for Q1 2027

Piramal Pharma Limited, a prominent player in the pharmaceutical and healthcare sectors, recently announced their financial results for the first quarter ending June 30, 2026. The company demonstrated substantial growth, reporting a 17% increase in revenue, totaling INR 2,270 crores, compared to INR 1,934 crores in Q1 2026.

Financial Highlights

• - CDMO (Contract Development and Manufacturing Organization) sector showed impressive growth, rising 19% from the previous year, reflecting the company’s robust operational strategy.
• - CHG (Complex Hospital Generics) also reported a 17% increase in revenue, showcasing the firm’s reliability in this competitive market.
• - The PCH (Consumer Healthcare) division achieved a 15% growth, demonstrating versatility across their product lines.
• - EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortization) surged by 72%, with an EBITDA margin of 12.5%, significantly improved from the previous year's 8.5%.
• - A noteworthy decrease in losses after tax, down to INR 69 crores, from INR 102 crores the prior year, indicates strategic progress in financial management.

Operational Improvements

The impressive growth was fueled by several factors: enhanced capacity utilization, disciplined pricing strategies, and operational excellence across their business segments. As a result, Piramal Pharma has established itself as a well-structured entity in a rapidly changing healthcare environment, focusing on generating sustained revenue while maintaining agility.

Piramal Pharma’s President, Nandini Piramal, states, “We initiated FY 2027 with a strong performance, as all three business divisions under our umbrella report revenue growth between 15% to 20%. Our CDMO segment witnessed broad growth both domestically and internationally, supported by a strengthened sales team and consistent order volumes.”

Strategic Moves and Developments

The company continues to see improvements in its operations with remarkable advancements:

• - The CDMO segment has witnessed a broad-based growth across facilities, backed by strong order flow and stringent execution of tasks.
• - The quality maintained at the Sellersville site in the USA has been acknowledged by the US FDA, reaffirming Piramal’s commitment to uncompromised production standards.
• - In addition, strategic partnerships have been established, notably with Ajinomoto Bio-Pharma Services, enhancing the capabilities in ADC (Antibody Drug Conjugates).
• - In the Consumer Healthcare division, brands have thrived, with a 23% year-on-year growth, propelled by online sales increasing by 40% within the same timeframe.

Future Outlook

With a solid foundation and strategic positioning, Piramal Pharma Ltd. anticipates continued growth throughout FY 2027, with an unwavering focus on enhancing their financial performance and market presence. The upcoming teleconference scheduled for July 30, 2026, will provide investors and analysts detailed insights into the company's trajectory and upcoming strategic initiatives.

Piramal Pharma Limited exemplifies resilience and adaptability within the pharmaceutical landscape, showcasing comprehensive strategies for sustained growth. As they solidify their market position through innovation and operational excellence, stakeholders remain aligned with the company’s vision for the future.

• ---

For more details, visit Piramal Pharma's LinkedIn or the official website.